Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint: Merck
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYNOTE-B21 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as adjuvant treatment, with or without radiotherapy, did …